G-CSF and Autologous Cord Blood Infusion in Cerebral Palsy
NCT ID: NCT02866331
Last Updated: 2016-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
88 participants
INTERVENTIONAL
2016-07-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuroregenerative Potential of Intravenous G-CSF and Autologous Peripheral Blood Stem Cells
NCT02983708
Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy
NCT01193660
Allogeneic UCB Therapy With EPO in Children With CP
NCT01991145
Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children
NCT01072370
Umbilical Cord Blood Therapy for Cerebral Palsy
NCT01528436
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CB + G-CSF
G-CSF (Leucostim)
CB (autologous cord blood)
CB + placebo
CB (autologous cord blood)
Placebo (Normal saline)
G-CSF
G-CSF (Leucostim)
Placebo
Placebo (Normal saline)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
G-CSF (Leucostim)
CB (autologous cord blood)
Placebo (Normal saline)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-severe type of cerebral palsy
* Willing to comply with all study procedures
Exclusion Criteria
* Presence of chromosomal abnormalities
* Unwillingness to participate clinical trial
* Presence of hypersensitivity reaction to G-CSF
* Evidence of hepatic, renal, cardiac dysfunctions
2 Years
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health & Welfare, Korea
OTHER_GOV
Hanyang University Seoul Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young-Ho Lee
Professor, Department of Pediatrics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hanyang University Hospital
Seoul, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP-CB-G-2016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.